Department of Cerebrovascular Medicine, Stroke Center, St. Mary's Hospital, Fukuoka, Japan.
Department of Neurosurgery, Stroke Center, St. Mary's Hospital, Fukuoka, Japan.
Interv Neuroradiol. 2020 Jun;26(3):341-345. doi: 10.1177/1591019919887821. Epub 2020 Mar 1.
Heparin-induced thrombocytopenia (HIT) is an immune-mediated complication of heparin exposure. A limited number of studies have reported cerebral venous sinus thrombosis accompanied by heparin-induced thrombocytopenia. Here, we present a case of successful endovascular therapy (EVT) without periprocedural heparinization in this situation.
A 47-year-old woman taking an oral contraceptive was admitted to our hospital with severe headache to be diagnosed as cerebral venous sinus thrombosis. Initially, she got improved by medical treatment with intravenous unfractionated heparin. However, she rapidly developed disturbance of consciousness and right hemiplegia due to cerebral venous sinus thrombosis accompanied by heparin-induced thrombocytopenia on the 14th hospital day. She underwent emergent EVT by immediate conversion of anticoagulation from heparin to argatroban. Despite a large clot burden, sufficient recanalization and anterograde venous drainage were re-established by combined EVT including aspiration, balloon sinoplasty, and local thrombolysis with urokinase infusion. She got improved immediately after the intervention and discharged home without any neurological sequelae after two months.
This unique case of cerebral venous sinus thrombosis worsened by occurrence of heparin-induced thrombocytopenia during the treatment finally resulted in excellent outcome highlights effectiveness of emergent endovascular intervention for critical cerebral venous sinus thrombosis resistant to initial medical treatment and of immediate establishment of effective anticoagulant strategy for both of heparin-induced thrombocytopenia and cerebral venous sinus thrombosis. Neuroendovascular therapy for cerebral venous sinus thrombosis using alternative argatroban to heparin for periprocedural anticoagulation might be safe and feasible.
肝素诱导的血小板减少症(HIT)是肝素暴露引起的免疫介导的并发症。少数研究报告了伴有肝素诱导的血小板减少症的脑静脉窦血栓形成。在此,我们报告了一例成功的血管内治疗(EVT)案例,在此情况下无需在围手术期使用肝素。
一名 47 岁女性,正在服用口服避孕药,因严重头痛入住我院,被诊断为脑静脉窦血栓形成。最初,她接受了静脉注射普通肝素的治疗,病情有所改善。然而,在第 14 天,由于肝素诱导的血小板减少症并发脑静脉窦血栓形成,她迅速出现意识障碍和右侧偏瘫。她立即将抗凝药物从肝素转换为阿加曲班,进行紧急 EVT。尽管血栓负荷大,但通过联合 EVT(包括抽吸、球囊成形术和局部尿激酶输注溶栓),仍成功建立了充分的再通和顺行静脉引流。她在介入治疗后立即得到改善,两个月后出院时无任何神经后遗症。
本例脑静脉窦血栓形成患者在治疗过程中因发生肝素诱导的血小板减少症而病情恶化,最终取得了良好的结果,突出了紧急血管内介入治疗对初始药物治疗无效的危急脑静脉窦血栓形成的有效性,以及对肝素诱导的血小板减少症和脑静脉窦血栓形成立即建立有效抗凝策略的重要性。在围手术期使用替代肝素的阿加曲班进行脑静脉窦血栓形成的神经血管内治疗可能是安全可行的。